Last reviewed · How we verify

CHEPLAPHARM — Portfolio Competitive Intelligence Brief

CHEPLAPHARM pipeline: 2 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Valcyte VALGANCICLOVIR marketed Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor Metabolic 2001-01-01
Xeloda capecitabine marketed Nucleoside Metabolic Inhibitor [EPC] Thymidylate synthase Oncology 1998-01-01

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. · 1 shared drug class
  2. Bristol-Myers Squibb · 1 shared drug class
  3. Extrovis · 1 shared drug class
  4. Hospira Inc · 1 shared drug class
  5. Novartis · 1 shared drug class
  6. Otsuka · 1 shared drug class
  7. Pfizer Inc. · 1 shared drug class
  8. Roche Palo · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for CHEPLAPHARM:

Cite this brief

Drug Landscape (2026). CHEPLAPHARM — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/cheplapharm. Accessed 2026-06-10.

Related